CNS Drugs 2012 Nov;26(11):975-82
Psychiatric Hospital Onze Lieve Vrouw, Brugge, Belgium.
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Eur Psychiatry 2007 Oct 7;22(7):433-43. Epub 2007 Jun 7.
Institute of Psychiatry, London, England.
Background: Naturalistic effectiveness trials of atypical antipsychotics are needed to provide broader information on efficacy, safety, and tolerability in patients with schizophrenia treated in a community practice setting.
Method: In this 26-week, open-label, multicentre study, patients with schizophrenia requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled were randomized to receive aripiprazole or an atypical antipsychotic standard of care (SOC) treatment (i.e. Read More
Clin Drug Investig 2010 ;30(3):187-93
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea.
Background: Despite the increasing evidence relating to strategies for switching between different antipsychotics, little evidence is available about predictors of improvement or worsening while switching. In a previous study, we compared different options for switching to aripiprazole and found that patients with schizophrenia switched to aripiprazole with immediate discontinuation of the previous antipsychotic showed an increase in symptom severity after 1 week.
Objective: To identify predictors of worsening in the first 4 weeks after the switch to aripiprazole in partial non-responders to previous treatments. Read More
Clin Neuropharmacol 2009 Sep-Oct;32(5):243-9
Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
Objective: To examine changes in cognitive function and clinical features after a switch from atypical antipsychotics to aripiprazole in patients with schizophrenia.
Method: Sixty-one patients with schizophrenia treated with atypical antipsychotics participated in this open-label, 26-week study. Antipsychotics were switched to aripiprazole, and neurocognitive functions were measured at 12 and 26 weeks using the computerized battery. Read More
Eur Psychiatry 2012 Oct 14;27(7):506-12. Epub 2011 Sep 14.
Universitair Centrum Sint Jozef, Kortenberg, Belgium.
Purpose: The aim of this study is to evaluate the effectiveness of 12-week treatment with aripiprazole in a broad range of patients suffering from schizophrenia by using a variety of physicians, caregivers and patients scales.
Subjects And Methods: A total of 361 in- or outpatients who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia received open-label aripiprazole (10-30 mg per day) in this 12-week, prospective, multicentre, uncontrolled study. The primary endpoint was the Clinical Global Impression-Improvement (CGI-I) scale which measured effectiveness of study medication, including efficacy, safety and tolerability. Read More